Skip to content

A human study to evaluate the effectiveness and safety of CAA on the fatigue improvement

A human study to evaluate the effectiveness and safety of CAA on the fatigue improvement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005613
Enrollment
120
Registered
2020-11-23
Start date
2021-03-17
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subject takes a test food or placebo once a day 3 capsules for 8 weeks

Sponsors

Seoul National University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and sign in informed consent form 2) Healthy adults aged 30 to under 60 who complain of fatigue

Exclusion criteria

Exclusion criteria: 1) Subject who is unable to perform cycle ergometer test 2) Subject who constantly exercised for 3 months prior to the first visit 3) Those with a high level of cardiopulmonary endurance 4) Subject has a body mass index (BMI) of 18.5 kg / m2 or less or 30.0kg / m2 or more 5) Subject is over alcoholic : Men > 210g/week, Women > 140g/week 6) Smoker and drug addict 7) Insomnia 8) Subject have any of the following (including past medical history) or are taking any related medicines: hyperlipidemia, asthma, musculoskeletal disorder and etc 9) Subject who had a surgical operation 6 months prior to the first visit 10) Subjects who consumed oriental medicine within 1 month prior to the first visit 11) Subjects who consumed functional foods or related food to affect physical performance and fatigue 12) A person who continuously used a fatigue recovery injection within one month of his/her first visit. 13) Subject with hypersensitivity to the test food or ingredients contained in the test food 14) Pregnant or lactating women or person who has pregnancy plan during the study 15) Subject in other clinical trials within one month of the first visit or plan to participate in other clinical trials during this human study period 16) Subject unable to use smartphone or computer 17) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

MeasureTime frame
fatigue related indicators

Secondary

MeasureTime frame
Clinical pathology examination(Vital sings, clinical laboratory test)

Countries

Korea, Republic of

Contacts

Public ContactByunggul LIM

Seoul National University

happenly@snu.ac.kr+82-2-880-7806

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 6, 2026